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ABSTRACT Quadriceps muscle phenotype varies widely between patients with chronic obstructive
pulmonary disease (COPD) and cannot be determined without muscle biopsy. We hypothesised that
measures of skeletal muscle adiposity could provide noninvasive biomarkers of muscle quality in this
population.
In 101 patients and 10 age-matched healthy controls, mid-thigh cross-sectional area, percentage
intramuscular fat and skeletal muscle attenuation were calculated using computed tomography images and
standard tissue attenuation ranges: fat -190– -30 HU; skeletal muscle -29–150 HU.
Mean¡SD percentage intramuscular fat was higher in the patient group (6.7¡3.5% versus 4.3¡1.2%,
p50.03). Both percentage intramuscular fat and skeletal muscle attenuation were associated with physical
activity level, exercise capacity and type I fibre proportion, independent of age, mid-thigh cross-sectional
area and quadriceps strength. Combined with transfer factor of the lung for carbon monoxide, these
variables could identify .80% of patients with fibre type shift with .65% specificity (area under the curve
0.83, 95% CI 0.72–0.95).
Skeletal muscle adiposity assessed by computed tomography reflects multiple aspects of COPD related
muscle dysfunction and may help to identify patients for trials of interventions targeted at specific muscle
phenotypes.
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Introduction
Skeletal muscle dysfunction is an important complication of chronic obstructive pulmonary disease
(COPD) occurring in mild as well as more advanced disease [1, 2]. It is largely driven by physical inactivity
and is most apparent in muscles of the lower limb, in particular the quadriceps [3, 4]. Quadriceps weakness
is associated with reduced exercise performance [5], poor health status [6], increased healthcare utilisation
[7] and mortality, independent of airflow obstruction [8]. Changes in the quadriceps include muscle
atrophy, loss of strength and endurance [9, 10], and a shift towards a less aerobic phenotype with reduced
type I fibre proportions, capillarity and oxidative enzymes [11, 12]. The degree and nature of impairment
varies widely between patients and cannot currently be predicted accurately without muscle biopsy [13].
The need for biomarkers of muscle phenotype has recently been highlighted, underscored by the prospect of
new pharmacotherapies that selectively target certain muscle characteristics [14]. For example, peroxisome
proliferator-activated receptor-d agonists or 59 AMP-activated protein kinase activators, which change the
fuel preference within skeletal muscle away from glycolysis towards fat oxidation.
Computed tomography (CT) is an established method to assess muscle mass or quantity [15]. Images can also
be analysed to assess muscle quality by the level of fatty infiltration of muscle, or muscle adiposity. Skeletal
muscle adiposity increases with age [16] and, independent of mass, is associated with muscle triglyceride
content [17], oxidative capacity [18], insulin resistance [19], muscle strength and power [20, 21], as well as
immobility and hip fracture [22, 23]. Little is known about muscle adiposity in patients with COPD, but given
the above, we predicted that CT-based measures could be valuable biomarkers of muscle phenotype in this
group. In particular, their use may help identify patients with type I to type II muscle fibre shift as candidates
for trials of targeted therapies. In this study, we hypothesised that mid-thigh intramuscular fat and muscle
attenuation would be associated with physical activity, exercise capacity and fibre shift.
Methods
Study design and subjects
Data were collated from patients with a diagnosis of COPD consistent with the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) criteria [24] who had previously participated in two clinical studies at the
Royal Brompton, King’s College or St Thomas’ Hospitals (London, UK). Some of the phenotypic data for
some of these patients has been previously reported [6, 25]. Exclusion criteria were: diagnoses of heart, renal or
liver failure; systemic inflammatory, metabolic or neuromuscular disorders; warfarin (bleeding risk from
biopsy); or an exacerbation within the preceding 4 weeks. Healthy age-matched controls with no history or
symptoms of respiratory or cardiovascular disease, or unresolved musculoskeletal injury were recruited by
local advertisement. All participants had provided written informed consent for studies approved by the Joint
University College London Committees on the Ethics of Human Research (Committee Alpha) and the Ethics
Committee of the Royal Brompton and Harefield NHS Foundation Trust.
Mid-thigh composition
CT was performed on a 64-slice CT scanner (SOMATOM Sensation 64; Siemens, Erlangen, Germany) with
the patient in a supine position. A single section of both mid-thighs, at a predefined level, was obtained
using the following acquisition parameters: 50 mA?s and 120 kVp. The protocol was modified to deliver a
reduced amount of radiation per scan. Images were viewed and analysed using SliceOMatic software
(version 4.3; TomoVision, Magog, QC, Canada).
Skeletal muscle and intramuscular fat were identified and quantified by use of standard Hounsfield unit
thresholds, which represent the physical properties of tissues expressed in numerical form (skeletal muscle
-29–150 HU; intramuscular fat -190– -30 HU) [26]. By specifying Hounsfield unit range, the software filters
by tissue type and allows each to be quantified in turn. Tissue perimeters can be altered manually where
necessary (fig. 1). Intramuscular fat was normalised to mid-thigh cross-sectional area (MTCSA) and
expressed as a percentage. Skeletal muscle attenuation was measured using the mean radiation attenuation
in Hounsfield units, which reflects macroscopic fatty muscle infiltration. A lower mean indicates less
attenuation and greater fat infiltration. These methods are highly reliable with reported intra- and inter-
class coefficients of variation between 0.2% and 4.8% [27, 28].
Additional measurements
Lung volumes, transfer factor of the lung for carbon monoxide (TLCO), fat mass and fat free mass index
(FFMI), daily step count and physical activity level (PAL), quadriceps maximum voluntary contraction
(QMVC) and twitch tension, vastus lateralis fibre type and shift, exercise capacity as assessed by incremental
shuttle walk test (ISWT) or 6-min walking distance (6MWD), and health-related quality of life were
assessed as described previously [6, 25] and in the online supplementary material.
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Statistical analysis
Normally distributed continuous data are presented as mean¡SD. Between-group comparisons were
performed using unpaired t-test, Chi-squared tests or one-way ANOVA, as appropriate. Associations
between measures of skeletal muscle adiposity and other variables were analysed using Pearson’s correlation
coefficients, and univariate and multivariate linear regression models incorporating age, MTCSA, QMVC
and TLCO % predicted as independent variables. For receiver operating characteristic (ROC) analysis,
percentage intramuscular fat and skeletal muscle attenuation were used alone or in combination to
discriminate subjects according to the presence of fibre shift. Statistical analysis and graphical presentations
were performed using SPSS version 19 (IBM Corp., Armonk, NY, USA) and GraphPad Prism 5 (GraphPad
Software Inc., San Diago, CA, USA), respectively. No attempt at imputation of missing data was made. A
p-value of ,0.05 was regarded as statistically significant.
Results
Subjects
CT data were available for 111 subjects: 101 COPD patients and 10 healthy age-matched controls (table 1).
Consistent with a diagnosis of COPD, patients had impaired lung function and reduced arterial blood
oxygen tension compared with controls. There were no significant differences in age, body mass index,
FFMI or arterial blood carbon dioxide tension between the patient and healthy control groups, but patients
had significantly reduced quadriceps strength, and mid-thigh and lean tissue cross-sectional area (table 1).
Percentage intramuscular fat was significantly elevated in patients with COPD compared with healthy
controls, with mean¡SD values of 6.6¡3.3% and 4.3¡1.2%, respectively (p50.03). In the patient group,
FIGURE 1 Mid-thigh compositional analysis based on a single slice computed tomography image. Tissues were
differentiated according to standardised Hounsfield unit thresholds; skeletal muscle (red) -29–150 HU, adipose tissue
(green) -190– -30 HU.
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TABLE 1 Subject characteristics
Healthy COPD p-value
Subjects 10 101
Males/females 4/6 60/41 0.20
Age years 68.0¡7.3 64.8¡7.6 0.21
Height cm 166¡9 169¡9 0.42
Weight kg 75.8¡14.6 70.0¡15.1 0.25
Body mass index kg?m-2 27.2¡3.7 24.5¡4.8 0.09
Fat mass kg 22.4¡9.7 27.0¡6.0 0.15
Fat-free mass kg 48.8¡12.1 47.7¡9.0 0.71
Fat-free mass index kg?m-2 16.9¡2.7 16.8¡2.4 0.85
Current/former/never-smoker 1/4/5 25/76/0 ,0.01
Smoking pack-years 10¡15 49¡24 ,0.01
FEV1 L 2.59¡0.64 1.08¡0.54 ,0.01
FEV1 % predicted 106¡13 41¡20 ,0.01
VC L 3.72¡0.95 3.00¡0.79 ,0.01
VC % predicted 121¡19 89¡19 ,0.01
FEV1/VC 69.9¡5.7 35.8¡13.8 ,0.01
TLC L 5.97¡1.32 7.34¡1.74 0.02
TLC % predicted 105¡11 123¡19 ,0.01
RV L 2.31¡0.55 4.26¡1.49 ,0.01
RV % predicted 102¡12 189¡60 ,0.01
RV/TLC 39¡6 56¡12 ,0.01
TLCO L 6.79¡1.52 3.49¡1.58 ,0.01
TLCO % predicted 87¡13 42¡19 ,0.01
PCO2 kPa 5.34¡0.47 5.20¡0.70 0.55
PO2 kPa 11.28¡1.02 9.61¡1.53 ,0.01
GOLD stage I/II/III/IV 4/26/31/40
GOLD grade A/B/C/D 9/4/19/69
Exacerbations in the past year 1 (0–2)
Medication n (%)
Long-acting b-agonist 85 (84)
Inhaled corticosteroid 85 (84)
Oral steroid .5 mg?day-1 8 (8)
Oxygen 18 (18)
Nocturnal NIV 8 (8)
SGRQ 8.2¡9.9 49.9¡19.0 ,0.01
QMVC kg 31.5¡9.2 26.7¡7.4 0.05
Quadriceps twitch force kg 7.4¡2.1 9.7¡3.1 0.04
Body composition (both thighs)
MTCSA cm2 221.8¡44.9 190.9¡47.6 0.04
Lean tissue cross-sectional area cm2 212.1¡42.5 178.0¡44.4 0.02
Lean tissue HU 42.3¡4.0 41.5¡4.8 0.63
Intramuscular fat cm2 11.8¡5.1 13.0¡7.4 0.64
Intramuscular fat % 4.30¡1.23 6.64¡3.32 0.03
Fibre type %#
I 48.9¡9.7 28.2¡12.5 ,0.01
IIa 44.3¡8.5 57.0¡13.4 0.01
IIx 3.2¡4.6 12.1¡13.1 0.02
II 47.5¡10.1 67.9¡15.2 ,0.01
Exercise capacity#
6MWD m 572¡81 341¡141 ,0.01
ISWT m 250¡132
Physical activity#
Wear time h per day 23.6¡0.5
Wear time % 98.3¡0.2
TEE kcal per day 1976¡332
Steps per day 4501¡3273
PAL 1.41¡0.17
Data are presented as n, mean¡SD or median (interquartile range), unless otherwise stated. COPD: chronic obstructive pulmonary
disease; FEV1: forced expiratory volume in 1 s; VC: vital capacity; TLC: total lung capacity; RV: residual volume; TLCO: transfer factor of
the lung for carbon monoxide; PCO2: carbon dioxide tension; PO2: oxygen tension; GOLD: Global Initiative for Chronic Obstructive Lung
Disease; NIV: noninvasive ventilation; SGRQ: St George’s respiratory questionnaire; QMVC: quadriceps maximum voluntary contraction;
MTCSA: mid-thigh cross-sectional area; 6MWD: 6-min walking distance; ISWT: incremental shuttle walk test; TEE: total energy
expenditure; PAL: physical activity level. #: COPD fibre type n548, ISWT n530, 6MWD and physical activity n569.
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values stratified by GOLD stage revealed that fat infiltration tended to be greater in those with advanced
disease, although the between group differences were not significant (GOLD I/II/III/IV 5.0¡0.5/5.9¡0.5/
7.9¡0.7/6.4¡0.5%) (table 1). Skeletal muscle attenuation was numerically, but not significantly, different
between patient and control groups (table 1), and was significantly reduced in the patients with most fat
infiltration (table 2).
Reproducibility
For all measures based on a standard CT image, the mean differences between two researchers, or repeat
assessments by the same researcher were less than 1% of the mean value for both assessments. The lower
95% confidence intervals of correlation coefficients for all assessments exceeded 0.99 and can be interpreted
as excellent (tables S1a and S1b). A subset of 29 patients had an additional CT scan following 3 months
participation in the placebo arm of a clinical trial. Overall, repeat assessments demonstrated good
reproducibility with all lower 95% confidence intervals of correlation coefficients exceeding 0.70 (table S1c).
Skeletal muscle adiposity and physical activity
Percentage intramuscular fat was negatively correlated with step count (r5 -0.27, p50.03) and PAL
(r5 -0.35, p50.003) (fig. 2), although only PAL was significantly reduced in patients in the upper
compared with the lower quartile of this measure (p50.04) (table 2). In a regression model, percentage
intramuscular fat was significantly associated with step count (b coefficient¡SE -258¡121, p50.04) and
PAL (b¡SE -0.02¡0.01, p50.007) independent of age, MTCSA and QMVC, but not TLCO % pred.
Skeletal muscle attenuation was positively correlated with step count (r50.36, p50.003) and PAL
(r50.35, p50.004) (fig. 2) and was significantly associated with these variables independent of age, MTCSA
and QMVC, but not TLCO % pred (step count b¡SE 206¡100, p50.02; PAL b¡SE 0.13¡0.01, p50.008).
Skeletal muscle adiposity and exercise capacity
Percentage intramuscular fat was negatively correlated with ISWT (r5 -0.45, p,0.001), and 6MWD when
analysed with (r5 -0.49, p50.001) and without (r5 -0.42, p50.02) control subjects (fig. 3). ISWT and
6MWD were significantly reduced among patients in the upper quartile of percentage intramuscular fat
compared with those in the lower quartile (table 2). Percentage intramuscular fat was significantly
associated with ISWT (b¡SE -16.0¡4.5, p,0.001) and 6MWD (b¡SE -19.5¡6.2, p50.004) independent
of age, MTCSA, QMVC and TLCO % pred.
Skeletal muscle attenuation was positively correlated with ISWT distance (r50.37, p50.002) and 6MWD
when analysed with (r50.57, p50.001) or without (r50.60, p50.001) control subjects (fig. 3), and was
significantly associated with exercise performance independent of age, MTCSA, QMVC and TLCO % pred
(ISWT b¡SE 9.8¡3.8, p50.001; 6MWD b¡SE 12.7¡3.8, p50.002).
Skeletal muscle adiposity and fibre shift
Percentage intramuscular fat was negatively correlated with the percentage of type I fibres when analysed
with (r5 -0.36, p50.006) and without (r5 -0.27, p50.05) control subjects (fig. S1). Percentage of type I
fibres was not significantly different between patients in the upper and lower quartile of percentage
intramuscular fat, but percentage of type IIx fibres was significantly greater in patients with most fat
infiltration (21.8¡18.4% versus 8.4¡8.7%, p50.04). Percentage intramuscular fat was independently
associated with percentage of type I fibres when considered with age, MTCSA and QMVC, but not TLCO %
pred (b¡SE -1.3¡0.6, p50.04). In a similar analysis, skeletal muscle attenuation was positively correlated
with percentage of type I fibres (r50.30, p50.02) (fig. S1b) but was not independently associated when the
other factors were considered.
To determine whether measures of skeletal muscle adiposity could predict fibre shift, a ROC analysis was
performed with fibre shift, defined as percentage of type I fibres f27%, as the dependent variable. TLCO %
pred was a stronger predictor of fibre shift than percentage intramuscular fat and skeletal muscle attenuation,
with area under the curve (AUC) values (95% CI) of 0.825 (0.709–0.940) and 0.648 (0.7494–0.802),
respectively (fig. 4). Combining measures of skeletal muscle adiposity with TLCO % pred, the AUC increased
to 0.833 (fig. 4). The curve profile also changed such that, with a greater emphasis on sensitivity than
specificity, measures of skeletal muscle adiposity could be used with TLCO % pred to identify.80% of patients
with fibre shift with .65% specificity (fig. 4).
Skeletal muscle adiposity and COPD characteristics
Neither percentage intramuscular fat nor skeletal muscle attenuation were significantly associated with sex,
body mass index, FFMI, MTCSA or QMVC. The latter measures were not as consistently related to physical
activity, exercise capacity or fibre shift as measures of skeletal muscle adiposity (table S2). Percentage
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intramuscular fat was not significantly associated with the other characteristics assessed except for fat mass
(r50.38, p,0.001). Skeletal muscle attenuation was associated with age (r5 -0.30, p50.002), TLCO % pred
(r50.30, p50.003), quadriceps twitch force (r50.37, p50.01), MTCSA (r50.22, p50.02) and fat mass
(r5 -0.19, p50.04).
TABLE 2 Clinical characteristics of chronic obstructive pulmonary disease patients stratified by
upper and lower quartile of percentage intramuscular fat
Lower quartile Upper quartile p-value
Subjects 25 25
Males/females 17/8 15/10 0.38
Age years 63.4¡7.3 66.4¡6.3 0.14
Height cm 169¡8 168.2¡8.7 0.60
Weight kg 63.9¡15.2 75.9¡15.5 0.01
Body mass index kg?m-2 22.0¡4.2 26.7¡5.2 0.001
Fat mass kg 16.1¡6.4 26.0¡9.5 0.001
Fat-free mass kg 47.7¡10.5 49.8¡8.0 0.43
Fat-free mass index kg?m-2 16.7¡2.6 17.1¡2.6 0.61
Smoking pack-years 49¡19 57¡29 0.32
FEV1 L 1.16¡0.62 0.98¡0.43 0.25
FEV1 % predicted 42¡21 37¡15 0.42
VC L 3.37¡0.84 2.83¡0.85 0.03
VC % predicted 94¡18 85¡17 0.08
FEV1/VC 32.6¡13.4 35.2¡11.8 0.49
TLC L 7.98¡1.5 6.97¡1.73 0.04
TLC % predicted 129¡14 116¡16 0.005
RV L 4.54¡1.25 4.09¡1.17 0.21
RV % predicted 201¡58 179¡42 0.14
RV/TLC 52¡15 59¡7 0.08
TLCO L 3.66¡1.72 2.98¡1.49 0.18
TLCO % predicted 42¡18 37¡18 0.35
PCO2 kPa 5.21¡0.43 5.27¡0.92 0.76
PO2 kPa 10.25¡1.38 9.11¡1.72 0.02
GOLD stage I/II/III/IV 1/7/6/11 0/5/13/7 0.19
GOLD grade A/B/C/D 2/2/3/18 1/0/2/17 0.27
Exacerbations in the past year 1 (0–2) 1 (0–2) 0.45
Medication n (%)
Long-acting b-agonist 21 (84) 22 (88) 0.46
Inhaled corticosteroid 21 (84) 22 (88) 0.20
Oral steroid .5 mg?day-1 3 (12) 2 (8) 0.50
Oxygen 4 (16) 8 (32) 0.16
Nocturnal NIV 0 (0) 4 (16) 0.03
SGRQ 47.2¡21.2 56.5¡13.5 0.09
QMVC kg 25.4¡8.2 26.1¡7.6 0.76
Quadriceps twitch force kg 10.3¡3.0 9.0¡2.7 0.21
Body composition (both thighs)
MTCSA cm2 190.9¡49.2 188.2¡50.4 0.85
Lean tissue cross-sectional area cm2 185.0¡48.4 167.1¡45.0 0.19
Lean tissue HU 44.9¡4.7 37.6¡4.9 ,0.001
Intramuscular fat cm2 5.8¡2.1 21.1¡7.1 ,0.001
Intramuscular fat % 2.94¡0.80 11.22¡2.20 ,0.001
Fibre type %#
I 29.3¡13.3 21.8¡10.5 0.14
IIa 60.9¡16.3 59.3¡11.6 0.79
IIx 8.4¡8.7 21.0¡18.4 0.04
II 69.3¡14.1 76.8¡11.4 0.68
Exercise capacity#
6MWD m 404¡166 188¡83 0.03
ISWT m 295¡138 172¡88 0.003
Physical activity#
Wear time h per day 23.7¡0.4 23.7¡0.3 0.87
Wear time % 98.7¡1.6 98.8¡1.1 0.81
TEE kcal per day 1961¡412 1925¡296 0.76
Steps per day 4632¡3407 3073¡2167 0.11
PAL 1.44¡0.17 1.33¡0.12 0.04
Data are presented as n, mean¡SD or median (interquartile range), unless otherwise stated. FEV1: forced expiratory volume in 1 s; VC:
vital capacity; TLC: total lung capacity; RV: residual volume; TLCO: transfer factor of the lung for carbon monoxide; PCO2: carbon dioxide
tension; PO2: oxygen tension; GOLD: Global Initiative for Chronic Obstructive Lung Disease; NIV: noninvasive ventilation; SGRQ: St
George’s respiratory questionnaire; QMVC: quadriceps maximum voluntary contraction; MTCSA: mid-thigh cross-sectional area; 6MWD:
6-min walking distance; ISWT: incremental shuttle walk test; TEE: total energy expenditure; PAL: physical activity level. #: comparison
limited to n514 versus n511 for fibre type, n56 versus n55 for 6MWD and n519 versus n518 for ISWT and physical activity measures.
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Discussion
We have investigated CT-based measures of skeletal muscle adiposity in patients with COPD. Patients had
a significantly elevated percentage of intramuscular fat compared with age-matched healthy controls.
Moderate significant associations were found between percentage intramuscular fat and skeletal muscle
attenuation, and measures of physical activity, exercise capacity and muscle fibre type independent of age,
quadriceps strength and MTCSA. By combining measures of skeletal muscle adiposity with TLCO, .80% of
subjects with quadriceps fibre shift could be identified with .65% specificity.
Significance of the findings
Our findings extend knowledge regarding the extent and nature of quadriceps muscle dysfunction in
COPD. Reductions in muscle mass, strength and endurance are well known phenomena, as are fibre shift
and loss of oxidative capacity [8, 9, 13]. Abnormally high levels of lipids have also been observed
microscopically in the quadriceps of patients with COPD both under the fascia [29] and within muscle
fibres [30, 31].
Image-based measures of quadriceps muscle structure may help to identify patients with specific muscle
phenotypes. Muscle biopsy data confirm that COPD muscle abnormalities are heterogeneous, unrelated to
muscle strength and that, on average, only 50% of unselected patients will have pathological fibre shift or
fibre atrophy [13]. For emerging pharmacotherapies that have fibre-type specific modes of action, such as
those that affect the transcriptional coactivator [32] or stimulate fatty acid oxidation [33], practical
biomarkers to identify relevant populations for study are desirable. Other biomarkers have been suggested
for this purpose, including 31P-magnetic resonance spectroscopy (MRS) [34] and plasma microRNA-1 [35].
CT measures are less expensive to undertake than 31P-MRS, and are likely to be more rapidly available and
more stable than any biomarker based on blood analysis.
Our findings also support data suggesting that emphysema (evaluated here via TLCO) rather than airflow
obstruction is the more closely associated with skeletal muscle abnormalities [36] and strength [37] than
FEV1, although in this it differs from the review by GOSKER et al. [11], which found FEV1 was more strongly
associated than TLCO at the study level. For study stratification, CT has the advantage that it can be scored
centrally and is less patient- and operator-dependent than gas transfer measurement.
The accumulation of fat in the skeletal muscle of patients with COPD may reflect an intermediate between a
type I to type II fibre shift and insulin resistance. Oxidative muscle fibres consume fats [38] and these results
are consistent with the observation that transgenic animal models with an increased skeletal muscle
oxidative fibre proportion have a reduced intramuscular triglyceride content, compared to wild-type
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controls, when exposed to a high-fat diet [39]. In humans, type I to type II fibre shift is associated with both
insulin resistance and obesity [40, 41], and intramuscular fat is associated with [42] and may exacerbate
insulin resistance [43]. Fat within skeletal muscle may also reflect fat tissue elsewhere in the body exceeding
its storage capacity and the subsequent release of fatty acids into the circulation. Thus, intramuscular fat
may also facilitate a stratified medicine approach as a biomarker of insulin resistance and cardiovascular risk
in COPD more generally. The former could be investigated by measures of fasting insulin levels, for
example, skeletal muscle adiposity with euglycaemic insulin clamp studies [44], and the latter by prospective
observation of cardiovascular events in patients with COPD whose levels of intramuscular fat are known.
Functional exercise performance was also associated with percentage intramuscular fat and skeletal muscle
attenuation. Given the link between physical inactivity and muscle fibre shift, this probably reflects reduced
quadriceps oxidative capacity and endurance, leading to early fatigue. This consolidates previous data in
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which our group demonstrated patients with fibre shift had poorer exercise performance than those
without, independent of differences in MTCSA and quadriceps strength [25].
Relationship to other work
Two small studies have previously demonstrated greater levels of intramuscular fat in patients with COPD
compared with healthy controls using CT and magnetic resonance imaging [45, 46]. Neither demonstrated
an association between measures of skeletal muscle adiposity and functional performance. SHEILDS et al. [47]
recently demonstrated increased intermuscular fat, as assessed by magnetic resonance imaging, in the
quadriceps of patients with COPD compared with healthy controls (mean increase 32%). As in the present
study, fat infiltration, but not muscle cross-sectional area, was associated with increased anaerobic
metabolism during exercise and reduced exercise performance [47]. Bioenergetic changes were not observed
in the biceps brachii despite patients having been selected on the basis of weakness in the quadriceps [47].
Critique of the method
Interobserver and interoccasion agreement for measures of skeletal muscle adiposity based on a standard
CT image were excellent, with narrower limits of agreement than those reported during measurement of
rectus femoris cross-sectional area with ultrasound [48]. Studies using CT report coefficients of variation
between 1.5% and 2.5% for tissue cross-sectional area and ,1% for muscle attenuation [49], with each HU
increase equivalent to a 1% increase in lipid concentration when assessed microscopically [17]. Differences
in serial measurements over 3 months in patients with stable COPD were also small and comparable to
those found with CT-based measures of muscle or adipose cross-sectional area as confirmed by axial
cadaver sections [50, 51]. The small measurement differences may be ascribed to operator error, particularly
in the manual correction of tissue margins, which are required in the absence of a fully automated analysis
procedure. Error relating to image acquisition should be minimal, particularly in comparison to other
modalities that rely on surface land-marking, for example ultrasound. Nonetheless, the marginally greater
differences between, as compared with within, observers underscores a need for training and
standardisation of observers for longitudinal measurements.
Muscle biopsies were obtained in a large subset of subjects in this study. Samples were used for fibre typing,
and to measure inflammatory markers and other mediators to fulfil the aims of primary studies.
Unfortunately, insufficient tissue remained to stain for intermyocellular and intramyocellular fat
deposition, which would have served as criterion measures to validate the CT-based measures as surrogate
markers of muscle adiposity. Direct measures of intramyocellular fat and myofilament density, and other
measures of muscle phenotype such as capillarisation, oxidative enzyme content and glucose handling,
would be helpful to examine in this population.
Future longitudinal work should explore the accumulation and mechanisms of intramuscular fat, the
responsiveness to change of these CT-based measurements and their ability to help predict clinical outcome,
for example treatment response, risk of admission or cardiovascular events. In older adults, 12 weeks of
high-intensity resistance training has been shown to increase quadriceps and hamstring muscle attenuation
by 5.4% and 5.5%, respectively, with concurrent changes in strength and mass [52]. Skeletal muscle
attenuation has also been used to predict community-based falls, hip fracture and functional mobility,
independent of strength [22, 23].
Conclusion
In conclusion, skeletal muscle adiposity assessed by CT imaging reflects important aspects of muscle
dysfunction in patients with COPD and may help to identify patients with fibre shift. Future work should
identify its responsiveness to intervention, both in proven therapies, for example exercise training, and with
novel drugs where specific muscle phenotypes may be expected to respond differently.
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